Mitochondrial targeting by use of lipid nanocapsules loaded with SV30, an analogue of the small-molecule Bcl-2 inhibitor HA14-1

0301 basic medicine MESH: Cell Line, Tumor MESH: Rats MESH: Mitochondria Antineoplastic Agents MESH: Glioma 03 medical and health sciences Nanocapsules MESH: Nanocapsules Cell Line, Tumor MESH: Caspase 3 Nitriles Animals MESH: Animals Benzopyrans [SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM] [SDV.BBM.BC] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM] Caspase 3 Glioma MESH: Lipids Lipids MESH: Nitriles Mitochondria Rats MESH: Proto-Oncogene Proteins c-bcl-2 Proto-Oncogene Proteins c-bcl-2 MESH: Benzopyrans MESH: Antineoplastic Agents
DOI: 10.1016/j.jconrel.2010.11.032 Publication Date: 2010-12-06T10:50:13Z
ABSTRACT
Taking advantage from the development of SV30, a new analogue of the pro-apoptotic molecule HA14-1, the aim of this study was to functionally evaluate SV30 and to develop safe nanocarriers for its administration. By using an inversion phase process, 57nm organic solvent-free lipid nanocapsules loaded with SV30 (SV30-LNCs) were formulated. Biological performance of SV30 and SV30-LNCs were evaluated on F98 cells that express Bax and Bcl-2, through survival assays, HPLC, flow cytometry, confocal microscopy and spectral imaging. We observed that SV30 alone or in combination with paclitaxel, etoposide or beam radiation could trigger cell death in a similar fashion to HA14-1. Although partially blocked by Z-VAD-fmk, this effect was coincident to caspase-3 activation. Hence, we established that SV30-LNCs improved SV30 biological activity together with a potentiation of the mitochondrial membrane potential decrease. Interestingly, flow cytometry and confocal analysis indicated that SV30 itself conferred to LNCs improved mitochondrial targeting skills that may present a great interest toward the development of mitochondria targeted nanomedicines.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (70)
CITATIONS (28)